Claims for Patent: 8,168,644

Summary for Patent: 8,168,644

Title:	Quinazolinone derivatives as tubulin polymerization inhibitors
Abstract:	The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization as well as pharmaceutical compositions comprising said compounds of formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, n, m and X have defined meanings.
Inventor(s):	Freyne; Eddy Jean Edgard (Rumst, BE), Mevellec; Laurence Anne (Louviers, FR), Vialard; Jorge Eduardo (Brussels, BE), Meyer; Christophe (Les Authieux sur le Port Saint Ouen, FR), Pasquier; Elisabeth Therese Jeanne (Val de Reuil, FR), Bourdrez; Xavier Marc (Saint Pierre du Vauvray, FR), Angibaud; Patrick Rene (Fontaine-Bellenger, FR)
Assignee:	Janssen Pharmaceutica NV (Beerse, BE)
Application Number:	12/934,733
Patent Claims:	1. A compound of formula (I) ##STR00077## including a stereochemically isomeric form thereof; wherein m is 0, 1 or 2 and when m is 0 then a direct bond is intended; n is 0, 1 or 2 and when n is 0 then a direct bond is intended; X is a direct bond, CR.sup.10R.sup.11, NR.sup.8 or O; R.sup.1 is aryl or Het; wherein aryl is phenyl or naphthalenyl; wherein Het is thienyl, pyrrolyl, pyrrolinyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, furanyl, piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, piperazinyl, pyrazinyl, triazinyl, indolizinyl, azaindolizinyl, indolyl, indolinyl, benzothienyl, indazolyl, benzoxazolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzotriazolyl, chromanyl, purinyl, quinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, naphthyridinyl or pteridinyl; two carbon atoms on aryl or Het can be bridged thereby forming a bi- or tricyclic moiety with a bivalent radical selected from --O--CH.sub.2--CH.sub.2--O-- (a-1), --CH.sub.2--O--CH.sub.2--O-- (a-2), --O--CH.sub.2--CH.sub.2--CH.sub.2-- (a-3), --O--CH.sub.2--CH.sub.2--NR.sup.8-- (a-4), --O--CR.sup.8.sub.2--O-- (a-5), --O--CH.sub.2--CH.sub.2-- (a-6), --CH.sub.2--N--CH.sub.2--CH.sub.2-- (a-7), --(CH.sub.2).sub.3-- (a-8), or --(CH.sub.2).sub.4-- (a-9); each aryl, Het, bridged aryl or bridged Het can be substituted with one, two, three, four or five substituents each independently selected from halo, cyano, nitro, hydroxycarbonyl, C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, C.sub.3-6cycloalkyl, amino C.sub.3-6cycloalkyl, haloC.sub.1-6alkyl, trihaloC.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.2-6alkenylcarbonyl, oxime, C.sub.1-6alkyloxime, amidoxime, --C.ident.C--CH.sub.2O--CH.sub.3, --C.ident.C--CH.sub.2N(CH.sub.3).sub.2, --C.ident.C--Si(CH.sub.3).sub.3, hydroxyC.sub.1-6alkyl, hydroxyC.sub.2-6alkenyl, hydroxyC.sub.2-6alkynyl, cyanoC.sub.1-6alkyl, cyano C.sub.2-6alkenyl, aminocarbonylC.sub.1-6alkyl, C.sub.1-6alkylsulfonylC.sub.1-6alkyl, C.sub.1-6alkylsulfonylC.sub.2-6alkenyl, C.sub.1-6alkylsulfonylC.sub.2-6alkynyl,-PO(OC.sub.1-6alkyl).sub.2, --B(OH).sub.2, --S--CH.sub.3, SF.sub.5, C.sub.1-6alkylsulfonyl, --NR.sup.8R.sup.9, --C.sub.1-6alkylNR.sup.8R.sup.9, --OR.sup.8, --C.sub.1-6alkylOR.sup.8, --CONR.sup.8R.sup.9, piperidinylC.sub.1-6alkyl, piperazinylC.sub.1-6alkyl, C.sub.1-6alkylpiperazinylC.sub.1-6alkyl, morpholinylC.sub.1-6alkyl, piperidinyl, piperazinyl, C.sub.1-6alkylpiperazinyl, morpholinyl, phenyl, thienyl, pyrazolyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, oxadiazolyl, imidazolyl, imidazolylC.sub.2-6alkynyl, C.sub.1-6alkylimidazolylC.sub.2-6alkynyl, cyanopyridinyl, phenylC.sub.1-6alkyl, phenylC.sub.2-6alkenyl, C.sub.1-6alkyloxyphenyl, trihaloC.sub.1-6alkylphenyl, methylpyrazolyl, halopyrimidinyl or dimethylaminopyrrolidinyl; R.sup.2 is hydrogen, methyl, ethyl, propyl, C.sub.3-6cycloalkyl, C.sub.3-6cycloalkylmethyl, fluor, phenyl, cyanophenyl or trifluoromethyl; R.sup.3 is methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, halo, trifluoromethyl, methyloxy or C.sub.1-6alkylcarbonyl; each R.sup.4, R.sup.5 and R.sup.6 is independently selected from hydrogen, halo, C.sub.1-6alkyloxy, cyano, C.sub.1-6alkyl, --OCH.sub.2CH.sub.2NR.sup.8R.sup.9, --CH.sub.2OCH.sub.2CH.sub.2NR.sup.8R.sup.9, --OCH.sub.2CH.sub.2CH.sub.2NR.sup.8R.sup.9 or C.sub.1-6alkyloxyC.sub.1-6alkyloxy; each R.sup.8 and R.sup.9 is independently selected from hydrogen, halo, C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, carbonyl, C.sub.1-6alkylsulfonylC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, dihydroxyC.sub.1-6alkyl, cyanoC.sub.1-6alkyl, trihaloC.sub.1-6alkyl, phenylC.sub.1-6alkyl, (diC.sub.1-6 alkyl)aminoC.sub.1-6alkyl, C.sub.1-6alkylsulfonyl, morpholinylC.sub.1-6alkyl, morpholinylcarbonyl, piperazinylC.sub.1-6alkyl, C.sub.1-6alkylpiperazinylC.sub.1-6alkyl, piperidinylC.sub.1-6alkyl, thiomorpholinylC.sub.1-6alkyl, C.sub.3-6cycloalkylmethyl, pyridinyl, pyrimidinyl, phenyl, halophenyl, oxanylC.sub.1-6alkyl, C.sub.1-6alkylsulfonylC.sub.1-6alkyl or C.sub.1-6alkylcarbonylaminoC.sub.1-6alkyl; each R.sup.10 and R.sup.11 is independently selected from hydrogen, methyl, hydroxyl; or R.sup.10 and R.sup.11 are taken together with the carbon atom to which they are attached to form a cyclopropyl ring or a radical of formula C(.dbd.O); a N-oxide form thereof, or a pharmaceutically acceptable addition salt thereof. 2. A compound as claimed in claim 1 wherein m is 0 or 1; R.sup.1 is phenyl or Het; wherein Het is pyridinyl, pyrimidinyl or benzothiazolyl; two carbon atoms on Het can be bridged with the bivalent radical (a-8); each phenyl or Het or bridged Het can be substituted with one or two substituents each independently selected from halo, cyano, C.sub.1-6alkyl, C.sub.2-6alkynyl, --C.ident.C--CH.sub.2O--CH.sub.3, hydroxyC.sub.2-6alkynyl or --OR.sup.8; R.sup.2 is methyl or ethyl; R.sup.3 is methyl, ethyl or hydroxyethyl; each R.sup.4, R.sup.5 and R.sup.6 is independently selected from hydrogen or halo; each R.sup.8 is hydrogen or C.sub.1-6alkyl; and each R.sup.10 and R.sup.11 is hydrogen. 3. A compound as claimed in claim 1 wherein m is 0 and n is 0; X is a direct bond or CH.sub.2; R.sup.1 is phenyl, pyridinyl or pyrimidinyl; when R.sup.1 is pyridinyl two carbon atoms on the pyridinyl can be bridged with the bivalent radical (a-8); each phenyl, pyridinyl or pyrimidinyl can be substituted with one or two substituents each independently selected from halo, cyano or C.sub.1-6alkyloxy; R.sup.2 is methyl; R.sup.3 is methyl or ethyl; and each R.sup.4, R.sup.5 and R.sup.6 is hydrogen. 4. A compound as claimed in claim 1 wherein R.sup.3 is methyl, ethyl, propyl, hydroxymethyl, halo, trifluoromethyl, methyloxy or C.sub.1-6alkylcarbonyl. 5. A compound as claimed in claim 1 which is selected from the following: ##STR00078## 6. A pharmaceutical composition comprising a compound claimed in claim 1 in a pharmaceutically acceptable carrier. 7. A composition of claim 6 comprising the combination with another anticancer agent chosen from the group consisting of cisplatin optionally combined with amifostine, carboplatin or oxaliplatin; paclitaxel, paclitaxel protein bound particles, Abraxane.TM., or docetaxel; camptothecin compounds; etoposide, etoposide phosphate or teniposide; vinblastine, vincristine or vinorelbine; 5-fluorouracil, leucovorin, gemcitabine, gemcitabine hcl, capecitabine, cladribine, fludarabine, nelarabine; cyclophosphamide, chlorambucil, carmustine, thiotepa, mephalan (melphalan), lomustine, altretamine, busulfan, dacarbazine, estramustine, ifosfamide optionally in combination with mesna, pipobroman, procarbazine, streptozocin, telozolomide, uracil; daunorubicin, doxorubicin optionally in combination with dexrazoxane, doxil, idarubicin, mitoxantrone, epirubicin, epirubicin hcl, valrubicin; picropodophilin; tetrocarcin A; prednisone; trastuzumab (HER2 antibody), rituximab (CD20 antibody), gemtuzumab, gemtuzumab ozogamicin, cetuximab, pertuzumab, bevacizumab, alemtuzumab, eculizumab, ibritumomab tiuxetan, nofetumomab, panitumumab, tositumomab, CNTO 328; tamoxifen, fulvestrant, toremifene, droloxifene, faslodex, raloxifene or letrozole; exemestane, anastrozole, letrazole, testolactone and vorozole; retinoids, vitamin D or retinoic acid and accutane; azacytidine or decitabine; premetrexed disodium; antinomycin D, bleomycin, mitomycin C, dactinomycin, carminomycin, daunomycin, levamisole, plicamycin, mithramycin; clofarabine, aminopterin, cytosine arabinoside or methotrexate, azacitidine, cytarabine, floxuridine, pentostatin, thioguanine; apoptosis inducing agents and antiangio egents; combrestatin, colchicines or nocodazole; flavoperidol, imatinib mesylate, erlotinib, gefitinib, dasatinib, lapatinib, lapatinib ditosylate, sorafenib, sunitinib, sunitinib maleate, temsirolimus; tipifarnib; sodium butyrate, suberoylanilide hydroxamide acid, depsipeptide, NVP-LAQ824, R306465, JNJ-26481585, trichostatin A, vorinostat; PS-341, MLN .41 or bortezomib; yondelis; telomestatin; batimastat, marimastat, prinostat or metastat; aldesleukin, denileukin diftitox, interferon alfa 2a, interferon alfa 2b, peginterferon alfa 2b; MAPK inhibitors; alitretinoin, bexarotene, tretinoin; arsenic trioxide; asparaginase; dromostanolone propionate, megestrol acetate, nandrolone decanoate, or phenpropionate; dexamethasone; abarelix, goserelin acetate, histrelin acetate, leuprolide acetate; thalidomide, lenalidomide; mercaptopurine, mitotane, pamidronate, pegademase, pegaspargase, rasburicase; ABT-737; PD98059, AZD6244, CI-1040; filgrastim, pegfilgrastim, sargramostim; erythropoietin or darbepoetin alfa; interleukin 11; oprelvekin; zoledronate, zoledronic acid; fentanyl; bisphosphonate; and palifermin.

Details for Patent 8,168,644

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-03-27
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2028-03-27
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2028-03-27
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2028-03-27